Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-126385
Filing Date
2026-03-26
Accepted
2026-03-26 16:36:45
Documents
83
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K rntx-20251231.htm   iXBRL 10-K 3471909
2 EX-19.1 rntx-ex19_1.htm EX-19.1 74522
3 EX-23.1 rntx-ex23_1.htm EX-23.1 6336
4 EX-23.2 rntx-ex23_2.htm EX-23.2 7974
5 EX-31.1 rntx-ex31_1.htm EX-31.1 12600
6 EX-31.2 rntx-ex31_2.htm EX-31.2 13610
7 EX-32.1 rntx-ex32_1.htm EX-32.1 8529
8 EX-32.2 rntx-ex32_2.htm EX-32.2 8493
  Complete submission text file 0001193125-26-126385.txt   13615903

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rntx-20251231.xsd EX-101.SCH 2111230
87 EXTRACTED XBRL INSTANCE DOCUMENT rntx-20251231_htm.xml XML 2069107
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38130 | Film No.: 26798814
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)